NASDAQ:ADIL Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis → The #1 Crypto That You Don’t Own… Yet (From Crypto 101 Media) (Ad) Free ADIL Stock Alerts $1.34 +0.03 (+2.29%) (As of 06/11/2024 ET) Add Compare Share Share Today's Range$1.23▼$1.3650-Day Range$1.13▼$2.9852-Week Range$0.77▼$14.00Volume92,605 shsAverage Volume3.68 million shsMarket Capitalization$5.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Adial Pharmaceuticals alerts: Email Address Ad Crypto 101 MediaThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening.Click here for all the details… About Adial Pharmaceuticals Stock (NASDAQ:ADIL)Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Read More ADIL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADIL Stock News HeadlinesJune 5, 2024 | investorplace.comMillionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025June 1, 2024 | americanbankingnews.comAdial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Large Decrease in Short InterestMay 29, 2024 | globenewswire.comAdial CEO to Present at the Spring MicroCap Rodeo Conference on June 6thMay 15, 2024 | msn.comADIL Stock Earnings: Adial Pharmaceuticals Misses EPS for Q1 2024May 15, 2024 | globenewswire.comAdial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateApril 24, 2024 | uk.investing.comAdial Pharmaceuticals secures new addiction treatment patentApril 22, 2024 | finanznachrichten.deAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark OfficeApril 22, 2024 | benzinga.comEXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US PatentApril 22, 2024 | globenewswire.comAdial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark OfficeApril 11, 2024 | msn.comWhy Bitcoin-Linked MicroStrategy Along With Adial Pharmaceuticals, Alpine Immune Sciences, Marin Software, And Tesla Are On Investors' Radars TodayApril 11, 2024 | msn.comDow Falls Over 1%; US Inflation Rate Accelerates In MarchApril 10, 2024 | marketwatch.comAdial Pharmaceuticals Shares Rise 78% After Positive Trial Data for AD04April 10, 2024 | msn.comAdial stock rallies 81% on data for alcohol abuse drugApril 10, 2024 | investorplace.comWhy Is Adial Pharmaceuticals (ADIL) Stock Up 59% Today?April 10, 2024 | msn.comEXCLUSIVE: Adial Pharmaceuticals' Potential Treatment For Alcohol Use Disorder Shows Encouraging Safety, Patient ComplianceApril 10, 2024 | finance.yahoo.comAdial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use DisorderApril 10, 2024 | globenewswire.comAdial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use DisorderApril 2, 2024 | globenewswire.comAdial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business UpdateMarch 19, 2024 | investing.comAdial Pharmaceuticals Inc (ADIL)March 16, 2024 | finance.yahoo.comMASI Apr 2024 120.000 callMarch 16, 2024 | finance.yahoo.comMASI Apr 2024 125.000 putMarch 11, 2024 | benzinga.comPeering Into Adial Pharmaceuticals's Recent Short InterestMarch 1, 2024 | globenewswire.comAdial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross ProceedsMarch 1, 2024 | investing.comAdial Pharmaceuticals secures new patent for AD04 drugFebruary 28, 2024 | msn.comWhy Adial Pharmaceuticals Stock Is Blasting OffSee More Headlines Receive ADIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/11/2024Next Earnings (Estimated)8/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ADIL CUSIPN/A CIK1513525 Webwww.adialpharma.com Phone(434) 422-9800FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-170.85% Return on Assets-150.00% Debt Debt-to-Equity RatioN/A Current Ratio9.48 Quick Ratio9.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book0.54Miscellaneous Outstanding Shares4,230,000Free Float3,620,000Market Cap$5.67 million OptionableNo Data Beta1.29 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Cary John Claiborne MBA (Age 63)CEO, President & Director Comp: $728.31kDr. Bankole A. Johnson DSc (Age 64)FRCPsych, M.D., M.Phil, Ph.D., Founder & Chief Medical Officer Comp: $435kMr. Joseph A. M. Truluck M.B.A. (Age 46)MBA, CFO, Treasurer & Secretary Comp: $358.49kMr. Tony Goodman (Age 60)COO & Director Comp: $33kMr. John R. Martin J.D.Chief Legal OfficerMs. Catherine FratilaControllerMore ExecutivesKey CompetitorsAeterna ZentarisNASDAQ:AEZSVincerx PharmaNASDAQ:VINCiBioNYSE:IBIOBullfrog AINASDAQ:BFRGLumos PharmaNASDAQ:LUMOView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 20,469 shares on 5/20/2024Ownership: 0.484%Kevin SchuylerBought 700 shares on 9/29/2023Total: $1,918.00 ($2.74/share)View All Insider TransactionsView All Institutional Transactions ADIL Stock Analysis - Frequently Asked Questions How have ADIL shares performed in 2024? Adial Pharmaceuticals' stock was trading at $1.86 at the beginning of 2024. Since then, ADIL stock has decreased by 28.0% and is now trading at $1.34. View the best growth stocks for 2024 here. When is Adial Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 19th 2024. View our ADIL earnings forecast. How were Adial Pharmaceuticals' earnings last quarter? Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) issued its earnings results on Tuesday, May, 14th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.17. When did Adial Pharmaceuticals' stock split? Adial Pharmaceuticals shares reverse split before market open on Monday, August 7th 2023. The 1-25 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Adial Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Aytu BioPharma (AYTU), T2 Biosystems (TTOO), AIM ImmunoTech (AIM), Tandem Diabetes Care (TNDM), vTv Therapeutics (VTVT), Acasti Pharma (ACST) and Adamis Pharmaceuticals (ADMP). When did Adial Pharmaceuticals IPO? Adial Pharmaceuticals (ADIL) raised $8 million in an initial public offering on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager. Who are Adial Pharmaceuticals' major shareholders? Adial Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.48%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James W Jr Newman, Kevin Schuyler and William B Stilley III. View institutional ownership trends. How do I buy shares of Adial Pharmaceuticals? Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADIL) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredNVDA to close the AI “wealth window’ June 25?On Tuesday, June 25, in front of executives from nearly every major tech company in existence, key leaders at ...Paradigm Direct | Sponsored"If I Die, I’d Trust 50% of My Daughters’ Inheritance in ONE Stock.""I'd Feel Secure Putting 50% of My Kids' Inheritance in THIS Stock" One Wall Street millionaire bought AAPL...Stansberry Research | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.